U.S. markets open in 44 minutes
  • S&P Futures

    3,799.50
    -43.00 (-1.12%)
     
  • Dow Futures

    30,525.00
    -317.00 (-1.03%)
     
  • Nasdaq Futures

    13,368.50
    -117.00 (-0.87%)
     
  • Russell 2000 Futures

    2,098.20
    -47.60 (-2.22%)
     
  • Crude Oil

    52.50
    -0.11 (-0.21%)
     
  • Gold

    1,839.00
    -11.90 (-0.64%)
     
  • Silver

    25.11
    -0.43 (-1.68%)
     
  • EUR/USD

    1.2107
    -0.0062 (-0.51%)
     
  • 10-Yr Bond

    1.0210
    -0.0190 (-1.83%)
     
  • Vix

    26.56
    +3.37 (+14.53%)
     
  • GBP/USD

    1.3683
    -0.0049 (-0.35%)
     
  • USD/JPY

    103.9950
    +0.3680 (+0.36%)
     
  • BTC-USD

    30,613.74
    -1,125.63 (-3.55%)
     
  • CMC Crypto 200

    616.31
    -23.61 (-3.69%)
     
  • FTSE 100

    6,572.72
    -81.29 (-1.22%)
     
  • Nikkei 225

    28,635.21
    +89.03 (+0.31%)
     

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT S.A.
·13 min read

Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2020:

  • 88,929 shares

  • €687 988.75

During the second half of 2020, total trading was:

  • On the buy side: 1,525,427 shares for a total amount of €6,221,316.16

  • On the sell side: 1,484,196 shares for a total amount of €6,066,211.46

During this same period, the number of trades were:

  • On the buy side: 2,623

  • On the sell side: 2,638

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

  • 27, 911 shares

  • €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements regarding the objective of its research and development programs. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2019 Universal Registration Document filed with the AMF on 27 May 2020 under n° D.20-0503 and in Section 2 “Risk Factors” of the Company’s Amendment to the Universal Registration Document filed with the AMF on 22 December 2020 under n° D.20-0503-A01, which are available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2019 Annual Report on Form 20-F filed with the SEC on May 27, 2020. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com


APPENDIX
H2 2020


Buy Side

Sell Side

Date

Number of executions

Number of shares

Traded amounts in EUR

Number of executions

Number of shares

Traded amount in EUR

TOTAL

2 623

1 525 427

6 221 316,16

2 638

1 484 196

6 066 211,46

01/07/2020

8

5001

24 555,04

2

1001

4 905,04

02/07/2020

10

6001

29 254,86

9

6001

29 554,86

03/07/2020

4

3001

14 554,89

5

3001

14 704,89

06/07/2020

8

5001

24 094,90

8

4001

19 454,90

07/07/2020

10

3001

14 354,90

8

4001

19 404,90

08/07/2020

2

1001

4 854,91

5

3001

14 854,91

09/07/2020

14

6001

28 804,92

5

2001

9 604,92

10/07/2020

5

3001

14 104,72

5

3001

14 254,72

13/07/2020

9

4001

18 704,73

4

1001

4 804,73

14/07/2020

12

7001

31 772,69

1

1

4,69

15/07/2020

2

1001

4 504,54

12

6001

27 804,54

16/07/2020

6

3001

13 804,64

6

2001

9 304,64

17/07/2020

3

2001

9 054,60

4

3001

13 804,60

20/07/2020

8

4001

19 304,62

19

10001

48 454,62

21/07/2020

6

3001

15 004,97

6

3001

15 154,97

22/07/2020

9

5001

23 804,93

1

1

4,93

23/07/2020

35

14001

65 957,73

30

18001

85 604,61

24/07/2020

6

5001

23 304,75

7

3001

14 004,75

27/07/2020

6

3001

13 804,70

3

1001

4 604,70

28/07/2020

9

4001

18 054,56

2

1001

4 554,56

29/07/2020

16

8001

34 390,48

6

2001

8 554,48

30/07/2020

12

7001

28 104,18

5

2001

7 954,18

31/07/2020

9

4001

16 853,98

18

9052

37 771,24

03/08/2020

4

1241

5 138,18

8

3241

13 751,14

04/08/2020

7

4001

17 104,34

9

2001

8 754,34

05/08/2020

30

13001

59 404,45

30

18001

82 412,45

06/08/2020

8

4001

17 554,40

7

3001

13 354,40

07/08/2020

6

4001

16 904,36

8

2001

8 454,36

10/08/2020

5

2001

8 454,24

2

1001

4 304,24

11/08/2020

7

5001

22 364,24

19

10001

44 504,24

12/08/2020

11

5001

21 954,38

7

4001

17 754,38

13/08/2020

9

3001

13 154,40

16

5001

22 204,40

14/08/2020

8

4001

17 504,46

1

1

4,46

17/08/2020

4

4001

17 904,38

11

6001

26 764,38

18/08/2020

14

10001

44 504,41

9

8001

36 104,41

19/08/2020

7

4001

17 704,44

9

6001

26 804,44

20/08/2020

6

4001

17 604,49

6

2001

8 904,49

21/08/2020

7

6001

26 704,41

10

8001

35 904,41

24/08/2020

13

6001

26 404,50

5

2001

9 004,50

25/08/2020

8

3001

13 004,39

3

1578

6 943,19

26/08/2020

6

2001

8 604,30

2

1001

4 354,30

27/08/2020

9

3001

12 694,36

2

1001

4 254,32

28/08/2020

17

2001

8 504,26

3

2001

8 604,26

31/08/2020

2

2001

8 504,29

3

2001

8 604,29

01/09/2020

6

3001

12 654,23

3

2001

8 604,23

02/09/2020

4

2001

8 304,18

3

1001

4 204,18

03/09/2020

9

4001

16 304,16

1

1

4,16

04/09/2020

5

2001

8 104,02

5

4001

16 404,02

07/09/2020

1

1

4,08

4

2001

8 304,08

08/09/2020

4

4001

16 304,15

1

1

4,15

09/09/2020

1

1

4,03

1

1

4,03

10/09/2020

9

4001

16 004,00

9

4001

16 204,00

11/09/2020

3

2038

8 335,39

10

4038

16 576,13

14/09/2020

6

5570

22 810,71

7

3533

14 570,02

15/09/2020

10

6001

24 564,16

12

10038

41 461,93

16/09/2020

14

12355

50 000,76

10

6759

27 377,22

17/09/2020

6

4338

17 401,90

5

3092

12 478,54

18/09/2020

15

13764

53 711,81

3

1785

7 122,15

21/09/2020

54

35711

130 617,19

23

23214

85 930,14

22/09/2020

56

37780

128 579,53

37

23425

79 505,48

23/09/2020

10

11053

37 777,14

37

21858

75 243,80

24/09/2020

42

26518

84 804,49

15

10566

33 938,12

25/09/2020

3

1001

3 303,22

71

40193

138 949,64

28/09/2020

42

28001

122 194,04

94

65580

280 622,39

29/09/2020

108

59184

289 427,62

81

44688

222 574,69

30/09/2020

77

46079

223 282,94

69

56966

276 415,17

01/10/2020

156

105679

445 527,89

108

65077

272 012,83

02/10/2020

64

30822

118 216,54

52

33382

129 847,68

05/10/2020

9

3697

14 719,50

11

4222

16 967,97

06/10/2020

1

1

3,98

1

1

3,98

07/10/2020

1

1

3,99

1

1

3,99

08/10/2020

12

6544

25 408,57

7

5158

20 154,63

09/10/2020

10

4761

18 497,21

3

1739

6 821,87

12/10/2020

39

20648

77 097,64

9

7489

27 937,17

13/10/2020

32

20443

72 373,38

18

16209

57 406,80

14/10/2020

12

5294

19 231,27

19

8435

30 823,04

15/10/2020

21

18208

68 856,25

54

30596

116 103,18

16/10/2020

6

5039

19 009,89

3

1279

4 844,91

19/10/2020

1

1

3,75

1

1

3,75

20/10/2020

13

6035

21 826,87

5

3018

11 005,80

21/10/2020

4

1692

5 999,90

4

4018

14 565,70

22/10/2020

16

5188

18 205,33

9

4605

16 316,83

23/10/2020

1

1190

4 176,90

3

2603

9 465,86

26/10/2020

24

13605

46 421,81

1

1

3,50

27/10/2020

42

32038

103 966,86

35

24282

78 944,36

28/10/2020

72

41189

128 615,54

43

44311

140 078,49

29/10/2020

20

11619

36 288,07

7

3454

10 852,04

30/10/2020

20

11623

36 080,25

26

17594

55 071,51

02/11/2020

47

31878

107 111,05

70

41096

137 798,09

03/11/2020

25

20530

69 640,13

36

19350

66 143,53

04/11/2020

27

19404

67 560,68

59

34582

120 337,38

05/11/2020

17

11841

41 744,28

46

19134

68 071,56

06/11/2020

35

19675

67 566,81

19

7002

24 253,56

09/11/2020

35

23518

80 982,51

45

28155

98 055,10

10/11/2020

25

19780

70 120,34

56

25327

89 877,35

11/11/2020

161

82363

354 327,31

245

109412

459 433,58

12/11/2020

56

35001

154 864,28

72

35001

155 314,28

13/11/2020

40

20101

83 015,18

32

18101

75 067,18

16/11/2020

59

30000

122 390,00

57

23863

98 453,67

17/11/2020

22

12001

47 694,11

37

12888

51 705,68

18/11/2020

9

4000

16 299,40

5

4000

16 444,00

19/11/2020

1

1

4,12

1

1

4,12

20/11/2020

4

2001

8 344,12

6

2251

9 401,62

23/11/2020

16

10001

41 074,19

17

9001

37 234,19

24/11/2020

30

13002

54 678,41

35

20001

84 534,13

25/11/2020

32

19000

80 960,12

30

18001

77 242,40

26/11/2020

17

11126

48 980,52

44

19001

84 004,27

27/11/2020

72

35001

172 560,61

71

37001

182 874,70

30/11/2020

44

26876

128 527,54

47

20008

98 479,34

01/12/2020

12

7001

31 714,47

11

7085

32 400,87

02/12/2020

14

8001

35 274,60

16

6002

26 520,70

03/12/2020

29

8953

39 698,47

16

8953

39 913,51

04/12/2020

9

4400

19 754,07

9

4896

22 143,93

07/12/2020

21

10602

47 624,48

21

11702

52 956,30

08/12/2020

28

13299

60 325,22

24

15562

71 181,83

09/12/2020

5

4001

18 496,70

6

4001

18 654,70

10/12/2020

12

6564

29 713,04

8

4601

20 852,65

11/12/2020

94

59167

247 064,47

72

40609

168 101,98

14/12/2020

48

31450

128 194,41

35

26439

108 050,57

15/12/2020

18

11746

47 469,01

19

9827

39 863,39

16/12/2020

18

11191

44 847,24

10

5532

22 431,84

17/12/2020

15

8629

34 338,71

22

18281

73 728,55

18/12/2020

8

5343

21 826,94

4

2672

10 968,95

21/12/2020

14

7007

27 755,33

2

2001

8 064,00

22/12/2020

6

4122

16 825,67

10

5122

20 939,24

23/12/2020

11

6928

27 938,15

7

6928

28 076,69

24/12/2020

9

6106

25 213,23

12

6162

25 604,31

28/12/2020

9

6465

25 871,03

9

5001

20 218,05

29/12/2020

8

4348

17 227,18

16

3869

15 467,69

30/12/2020

1

1

3,96

13

3589

14 473,60

31/12/2020

2

2001

7 988,07

4

1056

4 263,47

Attachment